Downregulated SOCS1 expression in various human cancers has been associated with dysregulation of cytokine receptor signaling pathways (63), whereas upregulated SOCS1 expression is associated with earlier tumor stages and better clinical outcomes in breast cancer (64). This evidence concerns the gene SOCS1 and breast carcinoma.